Hemab Therapeutics Holdings, Inc. (COAG) company profile
Close on Nov 17, 2026Market cap $1.82BP/E –Yield –
About Hemab Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Hemab Therapeutics Holdings, Inc. is listed on Nasdaq under the ticker COAG, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2025.
Company profile
Company
- Legal name
- Hemab Therapeutics Holdings, Inc.
- Headquarters
- Cambridge, MA
- Address
- 101 Main Street, Suite 1220 02142
- Phone
- (452) 138-7627
- Website
- hemab.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- COAG
- Exchange
- Nasdaq
- IPO date
- May 1, 2026
- Shares outstanding
- 47M, Jul 31, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2114044
- CUSIP
- 423494103
- ISIN
- US4234941031
- FIGI
- BBG021LKFW00
- Share class FIGI
- BBG021LKFWY3
- EIN
- 41-4241952
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Benny Sorensen | See Remarks, Director | – |
| Catherine Madigan | Chief Medical Officer | – |
| Mads Nikolaj Behrndt-Eriksen | See Remarks | 36,520 |
| Ananthram Sreenivasa Murthy | Chief Operating Officer | – |
| Keli Walbert | Director | – |
| RA Capital Nexus Fund IV, L.P. | Director | – |
| RA Capital Nexus Fund II, L.P. | Director | – |
| John Maraganore | Director | 17,974 |
| Linda Bain | Director | – |
| Laura Tadvalkar | Director | – |
| Akshay Vaishnaw | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 1, 2026
- Offer price
- $18.00
- Securities offered
- 16,750,000
- Gross proceeds
- $301.50M
- Exchange
- Nasdaq
- First trading day
- May 1, 2026
- First-day close
- $34.00+88.9%
- Lock-up ends (est.)
- Oct 28, 2026
“The initial public offering price per share is $18.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 1, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 27, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?